165,000 Shares in Flexion Therapeutics, Inc. (FLXN) Acquired by Ardsley Advisory Partners
Ardsley Advisory Partners acquired a new stake in shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 165,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,338,000. Ardsley Advisory Partners owned approximately 0.52% of Flexion Therapeutics as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fiduciary Trust Co. bought a new stake in shares of Flexion Therapeutics during the second quarter valued at approximately $101,000. IFP Advisors Inc increased its holdings in shares of Flexion Therapeutics by 24.5% during the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,000 shares in the last quarter. Advisor Group Inc. increased its holdings in shares of Flexion Therapeutics by 205.9% during the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 3,500 shares in the last quarter. Asset Management One Co. Ltd. bought a new stake in shares of Flexion Therapeutics during the first quarter valued at approximately $319,000. Finally, Voya Investment Management LLC increased its holdings in shares of Flexion Therapeutics by 25.8% during the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock valued at $261,000 after acquiring an additional 2,651 shares in the last quarter. Hedge funds and other institutional investors own 83.26% of the company’s stock.
Shares of Flexion Therapeutics, Inc. (NASDAQ FLXN) traded up 0.48% during midday trading on Tuesday, reaching $25.13. The company had a trading volume of 1,078,634 shares. The company’s market capitalization is $801.77 million. Flexion Therapeutics, Inc. has a one year low of $15.93 and a one year high of $32.25. The company has a 50-day moving average price of $25.16 and a 200 day moving average price of $22.58.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11). Equities analysts anticipate that Flexion Therapeutics, Inc. will post ($3.77) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/165000-shares-in-flexion-therapeutics-inc-flxn-acquired-by-ardsley-advisory-partners/1636875.html.
FLXN has been the subject of several recent research reports. Janney Montgomery Scott boosted their price objective on Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a report on Tuesday, October 10th. Wells Fargo & Company set a $39.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a report on Friday, October 6th. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Flexion Therapeutics in a report on Sunday, September 17th. Zacks Investment Research downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Finally, ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Flexion Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $88.50.
In related news, insider Yamo Deniz acquired 3,000 shares of the stock in a transaction on Friday, September 1st. The stock was acquired at an average price of $24.15 per share, for a total transaction of $72,450.00. Following the completion of the purchase, the insider now owns 5,000 shares of the company’s stock, valued at $120,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired 5,375 shares of company stock valued at $131,575 in the last quarter. 15.98% of the stock is owned by company insiders.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.